Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

February 01, 2006 (Vol. 26, No. 3)

Technical Note: Relieving the HTS Bottleneck for Kinases

Lack of Screening Assays Is Slowing Development of Selective Kinase Inhibitors

  • The central role of protein kinases in signal transduction and recent clinical success with small molecule kinase inhibitor drugs, most notably Gleevec (Novartis), have generated intense interest in kinase enzymes as therapeutic targets.1 Next to G-protein coupled receptors, protein kinases have become the most intensively screened target class.2 ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.